Skip to main content
    O

    Ocular Therapeutix Inc (OCUL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.01
    -0.20 (-3.22%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ocular Therapeutix Inc (OCUL) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Ocular Therapeutix (OCUL) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Ocular Therapeutix reported EPS of -$0.42, below the -$0.36 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    28%(11/40)
    Avg Surprise
    -25.42%

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.42
    Range-$0.44 - -$0.39
    15 analysts
    Revenue Consensus
    $14.03M
    Range$12.61M - $17.17M
    15 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.38
    Range-$0.43 - -$0.34
    6 analysts
    EPS Revisions
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.37-4.5%
    60d ago-$0.37-4.5%
    30d ago-$0.37-4.5%
    7d ago-$0.37-4.5%
    Current-$0.38
    Revenue Consensus
    $12.27M
    Range$11.00M - $13.30M
    7 analysts

    Next Report

    OCUL has an expected report date of Feb 3, 2027.

    OCUL Earnings Call

    The latest OCUL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, OCUL beat 11, missed 28 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $12.87M, down 11.5% from $14.54M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.42-$0.36-$0.37 - -$0.30-16.67%MissN/A64 up, 0 downNov 9, 2026$12.87M
    Jun 30, 2026-$0.35-$0.40-$0.42 - -$0.31+12.50%BeatN/A40 up, 1 downAug 3, 2026$13.47M
    Mar 31, 2026-$0.40-$0.31-$0.36 - -$0.26-29.03%MissN/A41 up, 0 downMay 5, 2026$10.79M
    Dec 31, 2025-$0.29-$0.34-$0.36 - -$0.31+14.71%BeatN/A31 up, 1 downFeb 5, 2026$13.25M
    Sep 30, 2025-$0.38-$0.35-$0.39 - -$0.31-8.57%MissN/A32 up, 0 downNov 4, 2025$14.54M
    Jun 30, 2025-$0.39-$0.35-$0.38 - -$0.30-11.43%MissN/A40 up, 3 downAug 5, 2025$13.46M
    Mar 31, 2025-$0.37-$0.28-$0.30 - -$0.25-32.14%MissN/A30 up, 3 downMay 5, 2025$10.70M
    Dec 31, 2024-$0.29-$0.22-$0.26 - -$0.14-31.82%MissN/A50 up, 3 downMar 3, 2025$17.08M
    Sep 30, 2024-$0.22-$0.21-$0.25 - -$0.16-4.76%MissN/A31 up, 0 downNov 14, 2024$15.43M
    Jun 30, 2024-$0.26-$0.21-$0.25 - -$0.14-23.81%MissN/A70 up, 0 downAug 7, 2024$16.44M
    Mar 31, 2024-$0.24-$0.18-$0.31 - -$0.14-33.33%MissN/A70 up, 0 downMay 7, 2024$14.77M
    Dec 31, 2023-$0.35-$0.30-$0.54 - -$0.19-16.67%MissN/A81 up, 0 downMar 11, 2024$14.80M
    Sep 30, 2023-$0.19-$0.25-$0.34 - -$0.21+24.00%BeatN/A70 up, 0 downNov 7, 2023$15.08M
    Jun 30, 2023-$0.26-$0.29-$0.41 - -$0.25+10.34%BeatN/A70 up, 0 downAug 7, 2023$15.19M
    Mar 31, 2023-$0.31-$0.24-$0.28 - -$0.24-29.17%MissN/A60 up, 0 downMay 8, 2023$13.37M
    Dec 31, 2022-$0.24-$0.25-$0.28 - -$0.20+4.00%BeatN/A60 up, 0 downMar 6, 2023$14.08M
    Sep 30, 2022-$0.30-$0.21-$0.28 - -$0.15-42.86%MissN/A50 up, 0 downNov 7, 2022$11.96M
    Jun 30, 2022-$0.21-$0.18N/A-16.67%MissN/AN/A0 up, 0 downAug 8, 2022$12.27M
    Mar 31, 2022-$0.25-$0.22N/A-13.64%MissN/A20 up, 0 downMay 9, 2022$13.19M
    Dec 31, 2021-$0.05-$0.23-$0.26 - -$0.21+78.26%BeatN/A4N/AFeb 28, 2022$12.31M
    Sep 30, 2021-$0.28-$0.26-$0.30 - -$0.20-7.69%MissN/A41 up, 0 downNov 8, 2021$12.15M
    Jun 30, 2021-$0.29-$0.21-$0.24 - -$0.16-38.10%MissN/A6N/AAug 9, 2021$11.72M
    Mar 31, 2021-$0.29-$0.21-$0.25 - -$0.17-38.10%MissN/A6N/AMay 5, 2021$7.34M
    Dec 31, 2020-$1.21-$0.17-$0.23 - -$0.07-611.76%MissN/A6N/AMar 11, 2021$7.35M
    Sep 30, 2020-$0.19-$0.25-$0.28 - -$0.20+24.00%BeatN/A4N/ANov 5, 2020$5.88M
    Jun 30, 2020-$0.64-$0.32-$0.35 - -$0.29-100.00%MissN/A5N/AAug 7, 2020$1.57M
    Mar 31, 2020-$0.41-$0.49N/A+16.33%BeatN/A3N/AMay 8, 2020$2.61M
    Dec 31, 2019-$0.53-$0.45-$0.46 - -$0.43-17.78%MissN/A3N/AMar 12, 2020$2.26M
    Sep 30, 2019-$0.45-$0.46-$0.52 - -$0.38+2.17%BeatN/A4N/ANov 12, 2019$829000
    Jun 30, 2019-$0.57-$0.48-$0.49 - -$0.46-18.75%MissN/A4N/AAug 7, 2019$650000
    Mar 31, 2019-$0.48-$0.42-$0.45 - -$0.38-14.29%MissN/A5N/AMay 10, 2019$492000
    Dec 31, 2018-$0.42-$0.38-$0.40 - -$0.37-10.53%MissN/A6N/AMar 7, 2019$504000
    Sep 30, 2018-$0.38-$0.37-$0.41 - -$0.34-2.70%MissN/A5N/ANov 7, 2018$498000
    Jun 30, 2018-$0.37-$0.37-$0.39 - -$0.360.00%In lineN/A4N/AAug 7, 2018$648000
    Mar 31, 2018-$0.40-$0.41-$0.44 - -$0.28+2.44%BeatN/A5N/AMay 8, 2018$340000
    Dec 31, 2017-$0.44-$0.52-$0.61 - -$0.47+15.38%BeatN/A5N/AMar 8, 2018$925000
    Sep 30, 2017-$0.54-$0.53-$0.60 - -$0.47-1.89%MissN/A5N/ANov 7, 2017$523000
    Jun 30, 2017-$0.64-$0.57-$0.61 - -$0.52-12.28%MissN/A4N/AAug 8, 2017N/A
    Mar 31, 2017-$0.58-$0.48N/A-20.83%MissN/AN/AN/AMay 5, 2017$475000
    Dec 31, 2016-$0.52-$0.45N/A-15.56%MissN/AN/AN/AMar 10, 2017$511000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.43, after -$1.01 the year before. It was -$1.80 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.43N/A
    Dec 31, 2024-$1.01N/A
    Dec 31, 2023-$1.11N/A
    Dec 31, 2022-$1.00N/A
    Dec 31, 2021-$0.91N/A
    Dec 31, 2020-$2.45N/A
    Dec 31, 2019-$2.03N/A
    Dec 31, 2018-$1.57N/A
    Dec 31, 2017-$2.20N/A
    Dec 31, 2016-$1.80N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,69510
    2026Q1Mar 31, 20265,29311
    2025Q3Sep 30, 20255,91010
    2025Q2Jun 30, 20257,91214
    2024Q4Dec 31, 20246,60211
    2024Q3Sep 30, 20244,33212
    2024Q2Jun 30, 20244,29211

    2026Q3 Earnings Call

    Opening remarks

    William Slattery Vice President of Investor Relations Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release and filed our quarterly report on Form 10-Q, outlining our financial results and business updates for the third quarter of 2026. We will begin today's call with prepared remarks summarizing recent business highlights from Dr. Pravin Dugel, Ocular's Executive Chairman, President and CEO; Dr. Nadia Waheed, Ocular's Chief Medical Officer; and David Robinson, Ocular's Global Chief Commercial Officer. Donald Notman, Ocular's Chief Operating Officer, will join for the question-and-answer session. We refer everyone to this morning's press release and our Form 10-Q for a comprehensive update of third quarter 2026 financial and business results. During today's call, certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially as a result of a variety of factors, including risks and uncertainties identified in the Risk Factors section of our annual report on Form 10-K and our other SEC filings. On today's call, we will discuss our investigational product candidate, AXPAXLI, also known as OTX-TKI, which is in development for wet age-related macular degeneration and non-proliferative diabetic retinopathy. As a reminder, the safety and efficacy of AXPAXLI have not been established by the FDA or any other regulatory authority, and AXPAXLI has not been approved for marketing. With that, I'd like to hand the call over to Dr. Pravin Dugel to review our recent updates. Pravin?

    Pravin Dugel Executive Chairman, President and CEO Thanks, Bill, and good morning, everyone. 2026 has been an extraordinary and truly transformational year for Ocular Therapeutix. We have achieved landmark Phase III superiority results in SOL-1, established a clear regulatory path forward toward our first potential approval for AXPAXLI in wet AMD, and continue to generate compelling clinical evidence showing AXPAXLI's durability and disease control. As we approach the end of the year, I believe we are in the strongest position in our company's 20-year history, with an extraordinary opportunity to fundamentally transform the treatment paradigm for retinal diseases. Today, while several bolus treatment agents are either approved or in development, AXPAXLI stands alone as the only intravitreal sustained-release maintenance agent with positive Phase III data in wet AMD. With the competitive landscape evolving significantly in recent months, we believe our opportunity has never been greater. I want to begin by addressing recent competitive developments because they reinforce the importance of the fundamental principles that have guided our AXPAXLI development strategy from the onset. These include the importance of TKI potency, drug delivery vehicle, and thoughtful clinical trial design, including rigorous patient selection. In drug development, molecular potency matters. The drug delivery vehicle matters.

    Frequently Asked Questions About OCUL

    When is Ocular Therapeutix's next earnings date?

    Ocular Therapeutix's next earnings report is expected for Feb 3, 2027.

    Did OCUL beat earnings estimates last quarter?

    No. Ocular Therapeutix reported EPS of -$0.42 for the quarter ended Sep 30, 2026, below the -$0.36 estimate by 16.67%.

    What EPS do analysts expect from OCUL next quarter?

    The consensus EPS estimate for Ocular Therapeutix for the quarter ending Dec 31, 2026 is -$0.42 from 15 analysts, with estimates from -$0.44 to -$0.39.

    How often does OCUL beat earnings estimates?

    Ocular Therapeutix beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -12.81%.